{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:02:13Z","timestamp":1791230533988,"version":"4.1.0"},"reference-count":397,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.pharmthera.2005.08.012","type":"journal-article","created":{"date-parts":[[2005,10,11]],"date-time":"2005-10-11T11:22:58Z","timestamp":1129029778000},"page":"386-414","source":"Crossref","is-referenced-by-count":147,"title":["Endothelin receptor antagonists"],"prefix":"10.1016","volume":"110","author":[{"given":"Sophie","family":"Motte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McEntee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Naeije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2005.08.012_bib1","series-title":"American College of Cardiology 50th Annual Scientific Session, Orlando, USA","article-title":"Effects of enrasentan, a non selective endothelin receptor antagonist in class II-III heart failure: results of the ENCOR trial (Enrasentan Cooperative Randomized Evaluation)","author":"Abraham","year":"2001"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI114965","article-title":"Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia","volume":"87","author":"Adnot","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib3","first-page":"L981","article-title":"Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia","volume":"278","author":"Aguirre","year":"2000","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI200421064","article-title":"Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention","volume":"114","author":"Ahn","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib5","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0735-1097(98)00440-9","article-title":"Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin: aggravation of this phenomenon in heritable hyperlipidemia","volume":"32","author":"Alexiou","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2005.08.012_bib7","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/00005344-198900135-00012","article-title":"The fate of radioiodinated endothelin-1 and endothelin-3 in the rat","volume":"13","author":"Anggard","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib8","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.1016\/S0021-9258(18)42300-9","article-title":"Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells","volume":"267","author":"Aramori","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib9","first-page":"219","article-title":"Molecular identification of O2 sensors and O2-sensitive potassium channels in the pulmonary circulation","volume":"475","author":"Archer","year":"2000","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0002-9149(02)03119-3","article-title":"Neurohormonal prediction of mortality following admission for decompensated heart failure","volume":"91","author":"Aronson","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1460-9592.2003.00120.x","article-title":"Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin","volume":"26","author":"Aronson","year":"2003","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9592.2001.01607.x","article-title":"Role of endothelin in modulation of heart rate variability in patients with decompensated heart failure","volume":"24","author":"Aronson","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib13","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/hmg\/4.12.2407","article-title":"Mutation of the endothelin-receptor B gene in Waardenburg\u2013Hirschsprung disease","volume":"4","author":"Attie","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib14","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1378\/chest.121.6.1860","article-title":"Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study","volume":"121","author":"Barst","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","article-title":"Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension","volume":"105","author":"Bauer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0092-8674(94)90018-3","article-title":"Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons","volume":"79","author":"Baynash","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0006-291X(89)91744-0","article-title":"Endothelin-1 increases intracellular calcium mobilization but not calcium uptake in rabbit vascular smooth muscle cells","volume":"164","author":"Bialecki","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/pupt.1999.0211","article-title":"ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat","volume":"12","author":"Bialecki","year":"1999","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib21","first-page":"1483","article-title":"Ambrisentan (Myogen)","volume":"3","author":"Billman","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":"Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1203\/00006450-200001000-00018","article-title":"Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension","volume":"47","author":"Black","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib24","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/01.CIR.0000087596.01416.2F","article-title":"Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow","volume":"108","author":"Black","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0008-6363(02)00318-8","article-title":"Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension","volume":"55","author":"Blumberg","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1152\/japplphysiol.00239.2002","article-title":"Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs","volume":"94","author":"Blumberg","year":"2003","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20020192","article-title":"ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men","volume":"104","author":"Bohm","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00005344-199307000-00007","article-title":"BQ123, an ETA receptor antagonist, attenuates endothelin-1-induced vasoconstriction in rat pulmonary circulation","volume":"22","author":"Bonvallet","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib29","first-page":"H1327","article-title":"BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats","volume":"266","author":"Bonvallet","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.HYP.31.3.766","article-title":"Chronic oral endothelin type A receptor antagonism in experimental heart failure","volume":"31","author":"Borgeson","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI114477","article-title":"Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide","volume":"85","author":"Boulanger","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0955-0674(97)80054-3","article-title":"How receptors talk to trimeric G proteins","volume":"9","author":"Bourne","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.300.2.442","article-title":"Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut-2-enoate-sodium (PD 155080)","volume":"300","author":"Brunner","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005344-199701000-00014","article-title":"Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion","volume":"29","author":"Burke","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3565(24)35311-X","article-title":"Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670","volume":"292","author":"Burrell","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib37","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJM199312233292618","article-title":"Endothelin-1 in pulmonary hypertension","volume":"329","author":"Cacoub","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib38","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/0002-8703(93)90555-N","article-title":"Plasma endothelin and pulmonary pressures in patients with congestive heart failure","volume":"126","author":"Cacoub","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0008-6363(96)00189-7","article-title":"Endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"33","author":"Cacoub","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/01.CIR.93.4.646","article-title":"Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure","volume":"93","author":"Cannan","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.33.2.753","article-title":"Role of endothelin in the increased vascular tone of patients with essential hypertension","volume":"33","author":"Cardillo","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.RES.69.2.447","article-title":"Endothelin induces a nonselective cation current in vascular smooth muscle cells","volume":"69","author":"Chen","year":"1991","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib44","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1152\/jappl.1995.79.6.2122","article-title":"Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats","volume":"79","author":"Chen","year":"1995","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00005344-199706000-00003","article-title":"The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague\u2013Dawley rats","volume":"29","author":"Chen","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib46","first-page":"896","article-title":"Effects of endothelin receptor A antagonist FR139317 on rats with congestive heart failure","volume":"22","author":"Chen","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.HDX.0000061696.83820.51","article-title":"Bosentan","volume":"5","author":"Cheng","year":"2003","journal-title":"Heart Dis"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0008-6363(98)00068-6","article-title":"Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs","volume":"39","author":"Choussat","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib49","first-page":"H2033","article-title":"Endothelin is a potent long-lasting vasoconstrictor in men","volume":"257","author":"Clarke","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib50","doi-asserted-by":"crossref","first-page":"32848","DOI":"10.1016\/S0021-9258(20)30069-7","article-title":"Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts","volume":"269","author":"Clerk","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib400","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/bj20021083","article-title":"Up-regulation of c-jun mRNA in cardiac myocytes requires the extracellular signal-regulated kinase cascade, but c-jun N-terminal kinases are required for efficient up-regulation of c-jun protein","volume":"368","author":"Clerk","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1242\/dev.125.5.813","article-title":"Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice","volume":"125","author":"Clouthier","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0014-5793(96)00212-8","article-title":"The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443","volume":"383","author":"Clozel","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0006-291X(92)90826-7","article-title":"The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo","volume":"186","author":"Clozel","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib55","first-page":"228","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib56","first-page":"840","article-title":"Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use","volume":"290","author":"Clozel","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0735-1097(01)01692-8","article-title":"Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction","volume":"39","author":"Clozel","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"Cody","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1388-9842(01)00210-0","article-title":"Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology\u2014WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME","volume":"3","author":"Coletta","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1388-9842(02)00040-5","article-title":"Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 and 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1388-9842(02)00176-9","article-title":"Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","article-title":"The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure","volume":"6","author":"Cotter","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib63","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0008-6363(98)00084-4","article-title":"Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction","volume":"39","author":"Cowburn","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(05)77807-7","article-title":"Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure","volume":"352","author":"Cowburn","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib65","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0735-1097(98)00663-9","article-title":"Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction","volume":"33","author":"Cowburn","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"Suppl. 8","key":"10.1016\/j.pharmthera.2005.08.012_bib67","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00005344-199322008-00008","article-title":"Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle","volume":"22","author":"Davenport","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib68","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1476-5381.1995.tb13322.x","article-title":"Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type","volume":"114","author":"Davenport","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib70","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1073\/pnas.85.24.9797","article-title":"Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor","volume":"85","author":"de Nucci","year":"1988","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib71","first-page":"L690","article-title":"ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat","volume":"269","author":"DiCarlo","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib72","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2125.2002.01158.x","article-title":"Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects","volume":"53","author":"Dingemanse","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib74","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00005344-200206000-00004","article-title":"Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist","volume":"39","author":"Dingemanse","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003088-200342030-00004","article-title":"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin","volume":"42","author":"Dingemanse","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib76","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-3565(24)37349-5","article-title":"EndothelinB receptors in rabbit pulmonary resistance arteries: effect of left ventricular dysfunction","volume":"284","author":"Docherty","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0014-2999(91)90233-G","article-title":"Effect of endothelin on total and regional coronary resistance and on myocardial contractility","volume":"192","author":"Domenech","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/01.CIR.92.1.106","article-title":"Role of endogenous endothelin-1 in experimental renal hypertension in dogs","volume":"92","author":"Donckier","year":"1995","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib79","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1097\/00005344-199800001-00077","article-title":"Pharmacologic characterization of the novel, orally available endothelin-A-selective antagonist SB 247083","volume":"31","author":"Douglas","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib80","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","article-title":"Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors","volume":"81","author":"Dupuis","year":"1996","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib81","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","article-title":"Human pulmonary circulation is an important site for both clearance and production of endothelin-1","volume":"94","author":"Dupuis","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib82","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0002-8703(98)70276-5","article-title":"Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension","volume":"135","author":"Dupuis","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib83","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0008-6363(98)00172-2","article-title":"Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure","volume":"39","author":"Dupuis","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib84","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.98.16.1684","article-title":"Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction","volume":"98","author":"Dupuis","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib85","first-page":"L571","article-title":"Dilator effect of endothelins in pulmonary circulation: changes associated with chronic hypoxia","volume":"265","author":"Eddahibi","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib86","first-page":"H828","article-title":"Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats","volume":"268","author":"Eddahibi","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/en.134.1.222","article-title":"Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells","volume":"134","author":"Eguchi","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ki.1992.255","article-title":"Endothelin-1 stimulates the Na+\/H+ and Na+\/HCO3-transporters in rabbit renal cortex","volume":"42","author":"Eiam-Ong","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib89","first-page":"R1260","article-title":"Normobaric hypoxia stimulates endothelin-1 gene expression in the rat","volume":"263","author":"Elton","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.HYP.18.2.165","article-title":"Cellular mechanism of endothelin-1 release by angiotensin and vasopressin","volume":"18","author":"Emori","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib91","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","article-title":"Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum","volume":"270","author":"Emoto","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib92","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/00004872-199816121-00008","article-title":"Renal haemodynamic effects of endothelin-1 and the ETA\/ETB antagonist TAK-044 in anaesthetized rabbits","volume":"16","author":"Evans","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jcp.1041450113","article-title":"[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a neuropeptide antagonist, blocks binding, Ca2(+)-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells","volume":"145","author":"Fabregat","year":"1990","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib94","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib96","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI115915","article-title":"Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression","volume":"90","author":"Firth","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib97","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(02)00107-1","article-title":"Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan","volume":"37","author":"Fouassier","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib98","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1161\/01.CIR.96.11.3963","article-title":"Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling","volume":"96","author":"Fraccarollo","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0009-9236(99)70066-4","article-title":"Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone","volume":"65","author":"Freed","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib100","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI118092","article-title":"Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression","volume":"96","author":"Fujisaki","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1071-9164(96)80025-X","article-title":"Plasma endothelin in congestive heart failure: a predictor of cardiac death?","volume":"2","author":"Galatius-Jensen","year":"1996","journal-title":"J Card Fail"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib102","first-page":"273","article-title":"Relation of endothelin-1 to survival in patients with primary pulmonary hypertension","volume":"26","author":"Gali\u00e8","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib103","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Gali\u00e8","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e8","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib105","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1172\/JCI117268","article-title":"Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade","volume":"93","author":"Garcia","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00004872-199008000-00006","article-title":"Positive inotropic action, natriuresis and atrial natriuretic factor release induced by endothelin in the conscious rat","volume":"8","author":"Garcia","year":"1990","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib107","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00005344-199504000-00018","article-title":"Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats","volume":"25","author":"Garjani","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000139542","article-title":"Contribution of endogenous endothelin-1 to the maintenance of vascular tone: role of nitric oxide","volume":"55","author":"Gellai","year":"1997","journal-title":"Pharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib109","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1097\/00005344-199800001-00124","article-title":"Increased monophasic action potential dispersion in endothelin-1-induced ventricular arrhythmias","volume":"31","author":"Geller","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib111","first-page":"339","article-title":"Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture","volume":"236","author":"Gillespie","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib112","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","article-title":"Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure","volume":"101","author":"Givertz","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib113","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","article-title":"Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade","volume":"109","author":"Goddard","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib114","first-page":"R1064","article-title":"Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs","volume":"255","author":"Goetz","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib115","first-page":"23","article-title":"Effect of aldosterone on the secretion of endothelin by ventricular fibroblasts","volume":"53","author":"Gong","year":"2001","journal-title":"Shengli Xuebao"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01869680","article-title":"Mechanisms of regulation of the Na+\/H+ exchanger","volume":"90","author":"Grinstein","year":"1986","journal-title":"J Membr Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib117","first-page":"1074","article-title":"Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts","volume":"263","author":"Grover","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib118","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/cvr\/27.9.1613","article-title":"The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion","volume":"27","author":"Grover","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib119","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/cvr\/27.12.2130","article-title":"Effects of endothelins on collagen turnover in cardiac fibroblasts","volume":"27","author":"Guarda","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib120","first-page":"F658","article-title":"Effects of endothelin on rat renal proximal tubule Na(+)-Pi cotransport and Na+\/H+ exchange","volume":"266","author":"Guntupalli","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib121","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(96)00494-3","article-title":"Bosentan improves renal regional blood flow in rats with experimental congestive heart failure","volume":"310","author":"Gurbanov","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib122","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1097\/00005344-199800001-00092","article-title":"Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension","volume":"31","author":"Haleen","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib123","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3181\/00379727-199-43342","article-title":"Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells","volume":"199","author":"Hassoun","year":"1992","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib124","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/cs0840427","article-title":"Endothelium-dependent modulation of responses to endothelin-I in human veins","volume":"84","author":"Haynes","year":"1993","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib125","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","article-title":"Contribution of endogenous generation of endothelin-1 to basal vascular tone","volume":"344","author":"Haynes","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib126","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1161\/01.CIR.93.10.1860","article-title":"Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans","volume":"93","author":"Haynes","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib127","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0014-2999(96)00807-2","article-title":"Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig","volume":"318","author":"Hemsen","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib128","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.1985.248.5.C550","article-title":"Characterization of a coronary vasoconstrictor produced by cultured endothelial cells","volume":"248","author":"Hickey","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib129","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1152\/jappl.1997.83.4.1209","article-title":"Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats","volume":"83","author":"Hill","year":"1997","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(89)90227-X","article-title":"Endothelin is a potent mitogen for rat vascular smooth muscle cells","volume":"78","author":"Hirata","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1165\/ajrcmb.23.1.4030","article-title":"Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice","volume":"23","author":"Hocher","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib132","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ng0496-445","article-title":"A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah\u2013Waardenburg syndrome)","volume":"12","author":"Hofstra","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib133","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-201x.1999.00502.x","article-title":"Haemodynamic influence and endothelin-1 plasma concentrations by selective or non-selective endothelin receptor antagonists in the pig in vivo","volume":"165","author":"Holm","year":"1999","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib134","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0008-6363(97)00291-5","article-title":"The ETA receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo","volume":"37","author":"Holm","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib135","unstructured":"Horn, E., Langleben, D., Frost, A., Hill, N. S., McLaughlin, V., Oudiz, R., et al., & for the STRIDE-1 Study Group. (2004). Chronic sitaxsentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 169, A210. A86"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib136","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-5793(91)80007-P","article-title":"Cloning and expression of human endothelin-1 receptor cDNA","volume":"287","author":"Hosoda","year":"1991","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib137","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/0092-8674(94)90017-5","article-title":"Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice","volume":"79","author":"Hosoda","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib138","doi-asserted-by":"crossref","first-page":"17384","DOI":"10.1016\/S0021-9258(18)41937-0","article-title":"Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor","volume":"267","author":"Hu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib139","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00005344-199809000-00024","article-title":"Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction","volume":"32","author":"Hu","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1183\/09031936.03.00025403a","article-title":"Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction","volume":"21","author":"Hubloue","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib141","first-page":"1057","article-title":"BMS-193884 and BMS-207940 Bristol\u2013Myers Squibb","volume":"3","author":"Hulpke-Wette","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"issue":"12 Suppl. S","key":"10.1016\/j.pharmthera.2005.08.012_bib142","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib143","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib144","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib145","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1097\/00005344-199800001-00121","article-title":"Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure","volume":"31","author":"Huntington","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib146","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/0735-1097(95)00568-4","article-title":"Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium","volume":"27","author":"Ichikawa","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib147","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0006-291X(91)91789-F","article-title":"An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis","volume":"178","author":"Ihara","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl. 12","key":"10.1016\/j.pharmthera.2005.08.012_bib148","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00005344-199204002-00005","article-title":"In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor","volume":"20","author":"Ihara","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib149","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.19.6.753","article-title":"Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells","volume":"19","author":"Imai","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0735-1097(98)00564-6","article-title":"Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters","volume":"33","author":"Inada","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib151","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1073\/pnas.86.8.2863","article-title":"The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes","volume":"86","author":"Inoue","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib152","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1016\/S0021-9258(18)63795-0","article-title":"The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression","volume":"264","author":"Inoue","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib153","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1073\/pnas.91.11.4892","article-title":"Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788","volume":"91","author":"Ishikawa","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib154","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI116579","article-title":"Endothelin-1 is an autocrine\/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes","volume":"92","author":"Ito","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1172\/JCI119274","article-title":"Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus","volume":"99","author":"Ivy","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib156","first-page":"L535","article-title":"Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension","volume":"274","author":"Ivy","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib157","first-page":"L758","article-title":"Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus","volume":"279","author":"Ivy","year":"2000","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib158","first-page":"L703","article-title":"Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats","volume":"282","author":"Ivy","year":"2002","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib159","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/01.CIR.98.19.2065","article-title":"Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats","volume":"98","author":"Iwanaga","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib160","doi-asserted-by":"crossref","first-page":"C1295","DOI":"10.1152\/ajpcell.1992.263.6.C1295","article-title":"Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells","volume":"263","author":"Janakidevi","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib161","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","article-title":"Effectiveness of a nonselective ET(A\/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension","volume":"103","author":"Jasmin","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib162","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1042\/CS20030139","article-title":"Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade","volume":"105","author":"Jasmin","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib163","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0196-9781(02)00078-5","article-title":"Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells","volume":"23","author":"Jougasaki","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib164","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0735-1097(02)02708-0","article-title":"RITZ-5: randomized intravenous tezosentan (an endothelin-A\/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study","volume":"41","author":"Kaluski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib166","doi-asserted-by":"crossref","first-page":"19126","DOI":"10.1016\/S0021-9258(17)46743-3","article-title":"Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores","volume":"268","author":"Karne","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib167","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/cvr\/27.12.2125","article-title":"Endothelin receptors in cultured adult rat cardiac fibroblasts","volume":"27","author":"Katwa","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib168","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0022-2828(90)90115-I","article-title":"Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells","volume":"22","author":"Kawaguchi","year":"1990","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib169","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1034\/j.1399-3003.2000.15d04.x","article-title":"Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension","volume":"15","author":"Kim","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib170","first-page":"F1051","article-title":"Endothelin: a potent renal and systemic vasoconstrictor peptide","volume":"256","author":"King","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib171","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib172","first-page":"H1197","article-title":"Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in the failing rat heart","volume":"276","author":"Kobayashi","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib173","first-page":"375","article-title":"Endothelin stimulates Na+\/H+ exchange in vascular smooth muscle cells","volume":"20","author":"Koh","year":"1990","journal-title":"Biochem Int"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib174","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0272-6386(12)80920-6","article-title":"Endothelins in the kidney: physiology and pathophysiology","volume":"22","author":"Kohan","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0272-6386(97)90004-4","article-title":"Endothelins in the normal and diseased kidney","volume":"29","author":"Kohan","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2005.08.012_bib176","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1097\/00005344-199526003-00109","article-title":"Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, TAK-044","volume":"26","author":"Kojima","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib177","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.ph.55.030193.000415","article-title":"Control of cardiac gene expression by mechanical stress","volume":"55","author":"Komuro","year":"1993","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib178","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-5793(88)80489-7","article-title":"Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells","volume":"238","author":"Komuro","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib179","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-2007-994352","article-title":"Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn","volume":"13","author":"Kumar","year":"1996","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1172\/JCI118033","article-title":"Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1","volume":"96","author":"Kurihara","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib181","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bbrc.1993.2236","article-title":"ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction","volume":"196","author":"LaDouceur","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib182","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1378\/chest.126.4.1377","article-title":"Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"126","author":"Langleben","year":"2004","journal-title":"Chest"},{"issue":"Suppl. 8","key":"10.1016\/j.pharmthera.2005.08.012_bib183","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/00005344-199322008-00004","article-title":"Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor","volume":"22","author":"Laporte","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib184","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0093-7754(03)00353-1","article-title":"Endothelin receptor antagonists in the treatment of prostate cancer","volume":"30","author":"Lassiter","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1540-0352(11)70025-7","article-title":"Clinical trials of atrasentan in hormone-refractory prostate cancer","volume":"2","author":"Lee","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib186","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1164\/ajrccm.164.7.2011011","article-title":"Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism","volume":"164","author":"Lee","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib187","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/01.CIR.83.5.1808","article-title":"Endothelin has biological actions at pathophysiological concentrations","volume":"83","author":"Lerman","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib188","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0735-1097(92)90183-N","article-title":"Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation","volume":"20","author":"Lerman","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib189","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib190","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1152\/jappl.1994.77.3.1451","article-title":"Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia","volume":"77","author":"Li","year":"1994","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib191","first-page":"L553","article-title":"Increased endothelin receptor gene expression in hypoxic rat lung","volume":"266","author":"Li","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib192","first-page":"R1906","article-title":"Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure","volume":"280","author":"Liu","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib193","first-page":"H2902","article-title":"Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart","volume":"280","author":"Loennechen","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib194","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ajh\/4.9.776","article-title":"Proliferation and Na+\/H+ exchange activation by endothelin in vascular smooth muscle cells","volume":"4","author":"Lonchampt","year":"1991","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1388-9842(01)00149-0","article-title":"Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology","volume":"3","author":"Louis","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib196","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0008-6363(96)00055-7","article-title":"Endothelin in chronic heart failure: current position and future prospects","volume":"31","author":"Love","year":"1996","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib197","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.CIR.94.9.2131","article-title":"Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors","volume":"94","author":"Love","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib198","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/pupt.2001.0298","article-title":"Effect of ET(A) receptor antagonist on pulmonary hypertension and vascular reactivity in rats with congestive heart failure","volume":"14","author":"Lucas","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib199","first-page":"E974","article-title":"Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure","volume":"279","author":"Luchner","year":"2000","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib200","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib201","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.101.2.142","article-title":"Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist","volume":"101","author":"MacCarthy","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib202","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199405000-00022","article-title":"Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles","volume":"23","author":"MacLean","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib203","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1006\/bbrc.1995.2560","article-title":"Endothelin induced collagen remodeling in experimental pulmonary hypertension","volume":"215","author":"Mansoor","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib204","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/01.CIR.82.6.2226","article-title":"Increased endothelin in experimental heart failure","volume":"82","author":"Margulies","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib205","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/01.CIR.84.4.1457","article-title":"Molecular and cellular mechanism of endothelin regulation. Implications for vascular function","volume":"84","author":"Masaki","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib206","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1067\/mtc.2001.113020","article-title":"Pulmonary metabolism of endothelin 1 during on-pump and beating heart coronary artery bypass operations","volume":"121","author":"Mathieu","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1440-1681.1996.tb02745.x","article-title":"Endothelins contract guinea-pig pulmonary artery and enhance its adrenergic response via ET(A) receptors","volume":"23","author":"Matsuda","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib208","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib209","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib210","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib211","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1097\/00005344-199800001-00125","article-title":"Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs","volume":"31","author":"Merkely","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib212","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI113876","article-title":"Integrated cardiac, renal, and endocrine actions of endothelin","volume":"83","author":"Miller","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib213","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0735-1097(99)00528-8","article-title":"Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"35","author":"Mishima","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib214","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/01.RES.73.5.887","article-title":"Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension","volume":"73","author":"Miyauchi","year":"1993","journal-title":"Circ Res"},{"issue":"5 Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib215","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1097\/00005344-200036051-00095","article-title":"Endothelin-1 and right-sided heart failure in rats: effects of an endothelin receptor antagonist on the failing right ventricle","volume":"36","author":"Miyauchi","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib216","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1067\/mhj.2000.109917","article-title":"Renal endothelin in heart failure and its relation to sodium excretion","volume":"140","author":"Modesti","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib217","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0008-6363(98)00169-2","article-title":"Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure","volume":"39","author":"Moe","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib218","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.RES.72.3.526","article-title":"Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium","volume":"72","author":"Molenaar","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib219","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1203\/01.PDR.0000049516.70216.2E","article-title":"Inhibition of in vivo constriction of fetal ductus arteriosus by endothelin receptor blockade in rats","volume":"53","author":"Momma","year":"2003","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib220","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0006-291X(02)00799-4","article-title":"Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium","volume":"295","author":"Morawietz","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl. 48","key":"10.1016\/j.pharmthera.2005.08.012_bib221","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1042\/CS103S237S","article-title":"Increased expression of endothelin-converting enzyme-1 in failing human myocardium","volume":"103","author":"Morawietz","year":"2002","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib222","first-page":"H686","article-title":"Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors","volume":"269","author":"Morbidelli","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib223","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.RES.72.1.20","article-title":"Endothelin as a neuropeptide. Cardiovascular effects in the brainstem of normotensive rats","volume":"72","author":"Mosqueda-Garcia","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib224","doi-asserted-by":"crossref","first-page":"H2482","DOI":"10.1152\/ajpheart.00419.2003","article-title":"Early activation of cardiac and renal endothelin systems in experimental heart failure","volume":"285","author":"Motte","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib225","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib226","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0008-6363(98)00159-X","article-title":"Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure","volume":"39","author":"Mulder","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib227","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.102.5.491","article-title":"Selective endothelin-A versus combined endothelin-A\/endothelin-B receptor blockade in rat chronic heart failure","volume":"102","author":"Mulder","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib228","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0143-4179(96)90038-4","article-title":"Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B)","volume":"30","author":"Mullol","year":"1996","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib229","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000032004.56585.2A","article-title":"Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice","volume":"106","author":"Murakoshi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib231","first-page":"L358","article-title":"Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs","volume":"276","author":"Muramatsu","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib232","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/jm020289q","article-title":"Biphenylsulfonamide endothelin receptor antagonists: 4. Discovery of N-[[2\u2032-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1\u2032-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist","volume":"46","author":"Murugesan","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib233","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1388-9842(99)00022-7","article-title":"G. Update of REACH-1 and MERIT-HF clinical trials in heart failure, Cardio.net Editorial Team","volume":"1","author":"Mylona","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib234","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0163-7258(01)00131-0","article-title":"Endothelins: vasoactive modulators of renal function in health and disease","volume":"90","author":"Naicker","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib235","first-page":"1347","article-title":"Expression of endothelin-1 in rats developing hypobaric hypoxia-induced pulmonary hypertension","volume":"79","author":"Nakanishi","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib236","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1126\/science.270.5236.633","article-title":"Relaxation of arterial smooth muscle by calcium sparks","volume":"270","author":"Nelson","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib237","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/01.RES.86.4.377","article-title":"Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart","volume":"86","author":"Neri Serneri","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib238","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJM200203213461212","article-title":"Treatment of primary pulmonary hypertension\u2014the next generation","volume":"346","author":"Newman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib239","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1021\/bi00187a035","article-title":"Phosphatidyl-l-serine is necessary for protein kinase C's high-affinity interaction with diacylglycerol-containing membranes","volume":"33","author":"Newton","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1440-1681.1999.03013.x","article-title":"Vascular biology of endothelin signal transduction","volume":"26","author":"Neylon","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib241","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.98.21.2323","article-title":"Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat","volume":"98","author":"Nguyen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib242","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/sj.bjp.0703466","article-title":"LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction","volume":"130","author":"Nguyen","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib243","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005344-200408000-00007","article-title":"Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension","volume":"44","author":"Nishida","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib244","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2004.06.028","article-title":"Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats","volume":"496","author":"Nishida","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib245","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","article-title":"Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels","volume":"26","author":"Nootens","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib246","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1172\/JCI114601","article-title":"Endothelin-1 mRNA is widely expressed in porcine and human tissues","volume":"85","author":"Nunez","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib247","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0002-8703(02)00127-8","article-title":"Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the randomized intravenous tezosentan study (RITZ-4)","volume":"144","author":"O'Connor","year":"2002","journal-title":"Am Heart J"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2005.08.012_bib248","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1067\/mhj.2003.156","article-title":"Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)","volume":"145","author":"O'Connor","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib249","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(03)00194-3","article-title":"Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the randomized intravenous tezosentan study (RITZ-4)","volume":"41","author":"O'Connor","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib251","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0006-291X(91)91806-N","article-title":"Molecular cloning of a non-isopeptide-selective human endothelin receptor","volume":"178","author":"Ogawa","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib250","first-page":"609","article-title":"Nonpeptide endothelin receptor antagonist: VI. Pharmacological characterization of SB 217242, a potent highly bioavailable endothelin receptor antagonist","volume":"276","author":"Ohlstein","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib252","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0008-6363(98)00205-3","article-title":"Comparison of the acute effects of a selective endothelin ETA and a mixed ETA\/ETB receptor antagonist in heart failure","volume":"39","author":"Ohnishi","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib253","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1097\/00005344-199800001-00066","article-title":"Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure","volume":"31","author":"Ohnishi","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib254","first-page":"H1727","article-title":"Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats","volume":"273","author":"Oie","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib255","first-page":"H868","article-title":"ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats","volume":"275","author":"Oie","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib256","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/0735-1097(94)00526-V","article-title":"Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy?","volume":"25","author":"Okada","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib257","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/01.CIR.92.1.114","article-title":"Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension","volume":"92","author":"Okada","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib258","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","article-title":"Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction","volume":"89","author":"Omland","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib259","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0022-3565(24)38076-0","article-title":"Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure","volume":"288","author":"Onishi","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib260","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/01.CIR.0000034444.31846.F4","article-title":"Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan","volume":"106","author":"Ooi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib261","first-page":"473","article-title":"Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist","volume":"276","author":"Opgenorth","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib262","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0002-9149(93)90543-L","article-title":"Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension","volume":"71","author":"Pacher","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib263","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","article-title":"Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure","volume":"27","author":"Pacher","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib264","series-title":"American College of Cardiology 51st Annual Scientific Sessions 2002","article-title":"Late breaking clinical trials II. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 trial program","author":"Packer","year":"2002"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib265","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.156.2.9607123","article-title":"Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist","volume":"156","author":"Park","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib266","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1165\/ajrcmb\/7.5.492","article-title":"Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts","volume":"7","author":"Peacock","year":"1992","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib267","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1681\/ASN.V2157","article-title":"Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products","volume":"2","author":"Perico","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib268","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1203\/00006450-200109000-00013","article-title":"TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets","volume":"50","author":"Perreault","year":"2001","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib269","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1023\/A:1007890126061","article-title":"Endothelin-A receptor antagonism during acute myocardial infarction in rats","volume":"14","author":"Pfeffer","year":"2000","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib270","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/01.CIR.99.14.1802","article-title":"Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium","volume":"99","author":"Pieske","year":"1999","journal-title":"Circulation"},{"issue":"12 Suppl. S","key":"10.1016\/j.pharmthera.2005.08.012_bib271","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"43","author":"Pietra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib272","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1440-1681.1999.03028.x","article-title":"Nitric oxide, endothelin and nephron transport: potential interactions","volume":"26","author":"Plato","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib273","first-page":"H984","article-title":"ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat","volume":"280","author":"Podesser","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib274","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.bjp.0701084","article-title":"Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocyte cells","volume":"121","author":"Ponicke","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oxfordjournals.eurheartj.a015228","article-title":"Prognostic value of plasma endothelin-1 in patients with chronic heart failure","volume":"18","author":"Pousset","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib276","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0022-3565(24)36925-3","article-title":"The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats","volume":"282","author":"Prie","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib277","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1016\/S0021-9258(17)32663-7","article-title":"Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells","volume":"269","author":"Prins","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib278","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0092-8674(94)90016-7","article-title":"A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease","volume":"79","author":"Puffenberger","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib279","first-page":"541","article-title":"Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure","volume":"22","author":"Qiu","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib280","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ki.1994.284","article-title":"Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology","volume":"46","author":"Rabelink","year":"1994","journal-title":"Kidney Int"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2005.08.012_bib281","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1097\/00005344-199526003-00117","article-title":"Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death","volume":"26","author":"Raschack","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib282","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/00005344-199800001-00043","article-title":"The endothelin-A antagonist LU 135 252 suppresses ischemic ventricular extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling","volume":"31","author":"Raschack","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib283","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-8703(87)90318-8","article-title":"Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration","volume":"114","author":"Rector","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib284","first-page":"342","article-title":"The case for treatment of selected patients with primary pulmonary hypertension","volume":"134","author":"Reeves","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib285","first-page":"H1555","article-title":"Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors","volume":"283","author":"Reinhart","year":"2002","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib286","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0006-291X(88)81025-8","article-title":"Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells","volume":"157","author":"Resink","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib287","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/01.CIR.91.3.771","article-title":"In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats","volume":"91","author":"Richard","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib288","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)60795-2","article-title":"Increased plasma concentrations of endothelin in congestive heart failure in humans","volume":"67","author":"Rodeheffer","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib289","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.0000053443.27512.33","article-title":"Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension","volume":"107","author":"Rondelet","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3476(05)81552-5","article-title":"Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension","volume":"123","author":"Rosenberg","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib291","unstructured":"Rosenzweig, E. B., Ivy, D. D., Widlitz, A. C., Doran, A. K., Claussen, L. R., Yung, D., et al. (2004). Effects of long-term Bosentan in children with pulmonary arterial hypertension. Am J Resp Crit Care Med, 169, A 210.A86."},{"key":"10.1016\/j.pharmthera.2005.08.012_bib292","first-page":"1110","article-title":"Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm","volume":"283","author":"Roux","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib293","first-page":"325","article-title":"Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology","volume":"46","author":"Rubanyi","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib296","first-page":"675","article-title":"Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone","volume":"48","author":"Ruetten","year":"1997","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib297","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-0083","article-title":"Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies","volume":"10","author":"Ryan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib298","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0735-1097(98)00439-2","article-title":"The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure","volume":"32","author":"Saad","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib299","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/CS19990302","article-title":"Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae","volume":"99","author":"Saetrum Opgaard","year":"2000","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib300","doi-asserted-by":"crossref","first-page":"14613","DOI":"10.1016\/S0021-9258(18)63739-1","article-title":"A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity","volume":"264","author":"Saida","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib301","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","article-title":"Inhibition of myocardial endothelin pathway improves long-term survival in heart failure","volume":"384","author":"Sakai","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib302","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0735-1097(96)00336-1","article-title":"Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats","volume":"28","author":"Sakai","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib303","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.CIR.93.6.1214","article-title":"Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart","volume":"9","author":"Sakai","year":"1996","journal-title":"Circulation"},{"issue":"5 Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib304","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/00005344-200036051-00031","article-title":"Hypotensive effect of endothelin-1 via endothelin-B-receptor pathway on pulmonary circulation is enhanced in rats with pulmonary hypertension","volume":"36","author":"Sakai","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib305","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-6147(92)90038-8","article-title":"Molecular characterization of endothelin receptors","volume":"13","author":"Sakurai","year":"1992","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib306","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00005344-199106000-00022","article-title":"Related articles, links proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow","volume":"17","author":"Salvati","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib307","first-page":"L668","article-title":"Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs","volume":"269","author":"Sato","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib308","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.bjp.0701923","article-title":"Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects","volume":"124","author":"Schmetterer","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib309","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1536\/jhj.41.79","article-title":"Therapy with the nonpeptide endothelin receptor antagonist 97-139 in a murine model of congestive heart failure: reduction of cardiac mass and myofiber hypertrophy","volume":"41","author":"Seta","year":"2000","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib401","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0008-6363(98)00150-3","article-title":"Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic?","volume":"39","author":"Sharif","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib310","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1006\/bbrc.1993.1240","article-title":"Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle","volume":"191","author":"Shetty","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib311","first-page":"L842","article-title":"Inhibition of voltage-gated K1 current in rat intrapulmonary arterial myocytes by endothelin-1","volume":"274","author":"Shimoda","year":"1998","journal-title":"Am J Physiol"},{"issue":"12 Suppl. S","key":"10.1016\/j.pharmthera.2005.08.012_bib312","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension","volume":"43","author":"Simonneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib313","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1096\/fasebj.4.12.2168326","article-title":"Cellular signaling by peptides of the endothelin gene family","volume":"4","author":"Simonson","year":"1990","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib314","first-page":"622","article-title":"The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides","volume":"119","author":"Simonson","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib315","first-page":"F790","article-title":"Ca2+ channels mediate protein tyrosine kinase activation by endothelin-1","volume":"270","author":"Simonson","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib316","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0006-291X(89)91108-X","article-title":"Endothelin evoked Ca2+ transients and oscillations in A10 vascular smooth muscle cells","volume":"163","author":"Simpson","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib317","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/0006-291X(90)90649-8","article-title":"Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance","volume":"167","author":"Sirvio","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib318","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"124","author":"Sitbon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib319","first-page":"1040","article-title":"Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist","volume":"264","author":"Sogabe","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib320","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1165\/ajrcmb.20.4.3356","article-title":"Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats","volume":"20","author":"Soma","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib321","first-page":"F411","article-title":"Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers","volume":"266","author":"Sorensen","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib322","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0735-1097(00)00649-5","article-title":"Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure, ET 003 Investigators","volume":"35","author":"Spieker","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib324","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.CIR.95.7.1918","article-title":"Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function","volume":"95","author":"Spinale","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib323","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1073\/pnas.88.16.7443","article-title":"Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction","volume":"88","author":"Spinella","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib325","first-page":"L614","article-title":"Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension","volume":"262","author":"Stelzner","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib326","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1742-7843.2004.pto_940107.x","article-title":"Effect of endothelin antagonism on contractility, intracellular calcium regulation and calcium regulatory protein expression in right ventricular hypertrophy of the rat","volume":"94","author":"Stessel","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib327","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib328","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.CIR.85.2.510","article-title":"Elevated endothelin-1 in heart failure and loss of normal response to postural change","volume":"85","author":"Stewart","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib329","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1476-5381.1992.tb14537.x","article-title":"Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction","volume":"107","author":"Sumner","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib330","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF00053029","article-title":"Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans","volume":"10","author":"Sutsch","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib331","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib332","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1006\/bbrc.1993.1291","article-title":"Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro","volume":"191","author":"Suzuki","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib333","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-3565(24)29434-9","article-title":"Pathophysiological roles of endogenous endothelin-1 in dogs with chronic heart failure produced by rapid right ventricular pacing","volume":"298","author":"Tadano","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib334","doi-asserted-by":"crossref","first-page":"21394","DOI":"10.1016\/S0021-9258(19)36936-4","article-title":"Purification and characterization of endothelin-converting enzyme from rat lung","volume":"268","author":"Takahashi","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib335","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0024-3205(98)00347-6","article-title":"Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension","volume":"63","author":"Takahashi","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib336","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09031936.01.00075501","article-title":"Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery","volume":"18","author":"Takahashi","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib337","first-page":"L1104","article-title":"Upregulation of ET-1 and its receptors and remodeling in small pulmonary veins under hypoxic conditions","volume":"280","author":"Takahashi","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib338","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0006-291X(90)90491-5","article-title":"The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae","volume":"170","author":"Takuwa","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib341","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1054\/jcaf.2002.126486","article-title":"Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?","volume":"8","author":"Teerlink","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib339","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1161\/01.CIR.90.5.2510","article-title":"Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)","volume":"90","author":"Teerlink","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib340","first-page":"H432","article-title":"Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs","volume":"268","author":"Teerlink","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib342","first-page":"H2629","article-title":"Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure","volume":"271","author":"Thomas","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib343","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/pupt.2000.0237","article-title":"Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist","volume":"13","author":"Tilton","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib344","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0735-1097(03)00556-4","article-title":"Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure","volume":"42","author":"Torre-Amione","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2005.08.012_bib345","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/00005344-199506263-00048","article-title":"Ventricular tachycardias induced by intracoronary administration of endothelin-1 in dogs","volume":"26","author":"Toth","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib346","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1345\/aph.1D080","article-title":"Tezosentan in the treatment of acute heart failure","volume":"37","author":"Tovar","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib347","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/0049825021000061624","article-title":"In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans","volume":"33","author":"Treiber","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib348","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/jpet.103.061614","article-title":"Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat","volume":"308","author":"Treiber","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib349","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO;2-I","article-title":"Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits","volume":"59","author":"Treinen","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib350","doi-asserted-by":"crossref","first-page":"21778","DOI":"10.1016\/S0021-9258(17)31872-0","article-title":"Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase","volume":"269","author":"Tsukahara","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib351","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0735-1097(94)90387-5","article-title":"Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure","volume":"23","author":"Tsutamoto","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib352","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0002-9149(99)80231-8","article-title":"Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure","volume":"76","author":"Tsutamoto","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib353","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0002-9149(00)01006-7","article-title":"Transcardiac extraction of circulating endothelin-1 across the failing heart","volume":"86","author":"Tsutamoto","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib354","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0167-5273(99)00062-5","article-title":"Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension","volume":"70","author":"Tutar","year":"1999","journal-title":"Int J Cardiol"},{"issue":"5 Suppl. 1","key":"10.1016\/j.pharmthera.2005.08.012_bib355","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1097\/00005344-200036051-00089","article-title":"Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats","volume":"36","author":"Ueno","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib356","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/pupt.1999.0158","article-title":"Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat","volume":"12","author":"Underwood","year":"1999","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib357","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cardfail.2004.04.001","article-title":"Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study","volume":"10","author":"Van Beneden","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib358","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mcp.2002.122473","article-title":"In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide","volume":"71","author":"Van Giersbergen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib359","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"Van Giersbergen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib360","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0006-291X(88)80970-7","article-title":"Molecular mechanism of action of the vasoconstrictor peptide endothelin","volume":"157","author":"Van Renterghem","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib361","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2125.2000.00171.x","article-title":"Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans","volume":"49","author":"Verhaar","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib362","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/01.CIR.81.4.1415","article-title":"Effect of endothelin-1 in man","volume":"81","author":"Vierhapper","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib363","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1021\/jm990170q","article-title":"Pyrrolidine-3-carboxylic acids as endothelin antagonists: 4. Side chain conformational restriction leads to ET(B) selectivity","volume":"42","author":"Von Geldern","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib364","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/ndt\/gfh471","article-title":"Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans","volume":"19","author":"Vuurmans","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib365","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(97)00296-9","article-title":"Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure","volume":"30","author":"Wada","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib366","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":"Polar secretion of endothelin-1 by cultured endothelial cells","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib367","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2362.1992.tb01463.x","article-title":"Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation","volume":"22","author":"Wagner","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib368","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/0006-291X(89)91377-6","article-title":"Two distinct types of endothelin receptors are present on chick cardiac membranes","volume":"161","author":"Watanabe","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib369","first-page":"1124","article-title":"BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist","volume":"272","author":"Webb","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib370","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib371","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib372","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/01.CIR.89.4.1580","article-title":"Endothelin in human congestive heart failure","volume":"89","author":"Wei","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib373","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1096\/fasebj.9.2.7781921","article-title":"The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels","volume":"9","author":"Weir","year":"1995","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib374","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00005344-200110000-00013","article-title":"Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction","volume":"38","author":"Willette","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib375","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0006-291X(91)91601-8","article-title":"Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes","volume":"175","author":"Williams","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib376","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jmg.30.10.852","article-title":"DiGeorge syndrome: part of CATCH 22","volume":"30","author":"Wilson","year":"1993","journal-title":"J Med Genet"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib377","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/jm9505369","article-title":"2,4-Diarylpyrrolidine-3-carboxylic acids\u2013potent ETA selective endothelin receptor antagonists: 1. Discovery of A-127722","volume":"39","author":"Winn","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib378","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","article-title":"Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling","volume":"25","author":"Wort","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib379","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/jm9700068","article-title":"Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist","volume":"40","author":"Wu","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib380","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/jm030528p","article-title":"Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist","volume":"47","author":"Wu","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib381","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0092-8674(94)90425-1","article-title":"ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1","volume":"78","author":"Xu","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib382","first-page":"R1290","article-title":"Role of ET(A) and ET(B) receptors in endothelin-1-induced adrenal catecholamine secretion in vivo","volume":"272","author":"Yamaguchi","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib383","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0008-6363(00)00024-9","article-title":"Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and \u00aboverdrive\u00bb of the endothelin system","volume":"46","author":"Yamamoto","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib384","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1161\/01.CIR.99.16.2171","article-title":"Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function","volume":"99","author":"Yamauchi-Kohno","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib385","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib386","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1097\/00004872-198812040-00056","article-title":"A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels","volume":"6","author":"Yanagisawa","year":"1988","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib387","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1242\/dev.125.5.825","article-title":"Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene","volume":"125","author":"Yanagisawa","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib388","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.100.1.5","article-title":"Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade","volume":"100","author":"Yang","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib389","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib390","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1172\/JCI116805","article-title":"Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells","volume":"92","author":"Yokokawa","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib391","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jjp.53.259","article-title":"The arrhythmogenic action of endothelin in rats","volume":"53","author":"Yorikane","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib392","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0006-291X(05)81080-0","article-title":"Evidence for direct arrhythmogenic action of endothelin","volume":"173","author":"Yorikane","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib393","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.84.6.2280","article-title":"Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation","volume":"84","author":"Yoshibayashi","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib394","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1165\/ajrcmb\/9.4.429","article-title":"BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells","volume":"9","author":"Zamora","year":"1993","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib395","first-page":"L101","article-title":"Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats","volume":"270","author":"Zamora","year":"1996","journal-title":"Am J Physiol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2005.08.012_bib396","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1097\/00005344-199526003-00085","article-title":"ETB receptors promote proliferation and migration of endothelial cells","volume":"26","author":"Ziche","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib397","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.99.16.2118","article-title":"Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure","volume":"99","author":"Zolk","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib398","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0008-6363(01)00468-0","article-title":"Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2) 27 rats","volume":"53","author":"Zolk","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2005.08.012_bib399","first-page":"2","article-title":"Novel mechanisms of sympatho-excitation in chronic heart failure","volume":"3","author":"Zucker","year":"2002","journal-title":"Heart Fail Monit"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:02:25Z","timestamp":1736028145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725805001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":397,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0163725805001865"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2005.08.012","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}